Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer

A main limitation of therapies that selectively target kinase signaling pathways is the emergence of secondary drug resistance. Cetuximab, a monoclonal antibody that binds the extracellular domain of EGFR, is effective in a subset of KRAS wild type metastatic colorectal cancers(1). After an initial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Misale, Sandra, Yaeger, Rona, Hobor, Sebastijan, Scala, Elisa, Janakiraman, Manickam, Liska, David, Valtorta, Emanuele, Schiavo, Roberta, Buscarino, Michela, Siravegna, Giulia, Bencardino, Katia, Cercek, Andrea, Chen, Chin-Tung, Veronese, Silvio, Zanon, Carlo, Sartore-Bianchi, Andrea, Gambacorta, Marcello, Gallicchio, Margherita, Vakiani, Efsevia, Boscaro, Valentina, Medico, Enzo, Weiser, Martin, Siena, Salvatore, Di Nicolantonio, Federica, Solit, David, Bardelli, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3927413/
https://ncbi.nlm.nih.gov/pubmed/22722830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature11156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados